Full Press Release Details
MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion 1Q, 2011* 2. MN 166 Study for Opioid Withdrawal Anticipated completion in 2H, 2010* Potential upcoming Business Deals: 1. Secure a global partnership for MN 166 2. Secure a strategic partnership for MN 221 3. Secure partnership for non core assets to enable continued clinical development Current MediciNova Current MediciNova Strategy Strategy *Anticipated completion dates based on current projections
Kirk Johnson, Ph.D. Chief Scientific Officer 20 Avigen, Genesoft Pharmaceuticals, Chiron Corporation Michael Coffee Michael Coffee Chief Business Officer 25 Chief Business Officer, Avigen, President of Elan Pharmaceuticals, North America Masatsune Masatsune Okajima, CMA Okajima , CMA , CMA VP, Head of Japanese Office 18 Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank Management Team with Management Team with Global Experience Global Experience MediciNova, Inc. 2010 9 On going Clinical Activity: 1.
Currently MediciNova has in licensed 8 compounds 6 7 Commercially Attractive Commercially Attractive Diversified Portfolio Diversified Portfolio Stage of development when licensed: Work completed by MediciNova (MNOV) since in license: MediciNova, Inc. 2010 MediciNova, Inc. 2010 8 Leadership Years Experience Background Yuichi Iwaki, MD, PhD Yuichi Iwaki, MD, PhD CEO President 34 Professor at USC, formerly Professor at University of Pittsburgh; Advisor to JAFCO, Tanabe Shintaro Shintaro Asako, CPA Asako , CPA , CPA Chief Financial Officer 12 KPMG USA (Audit), Arthur Andersen USA Kirk Johnson, Ph.D.
Continue internal development of compound towards commercialization (focus on US market) 2. Seek partnership for further development of compouds Manufacture Market Market Manufacture Out License Development In License MediciNova 4 MediciNova, Inc. 2010 Why Japan? Why Japan? Recent Japanese pharma blockbusters Mid size pharma firms generally must partner to reach global markets Opportunity for US/global developer that understands Japan Need for globalization by Japanese Pharma as market lags behind USA and European markets *PharmaLive Special Reports, Top 50 Pharmaceutical Companies Their Pipelines 2010; August 1, 2010 5 MediciNova, Inc. 2010 $0 MediciNova, Inc. 2010 History : Portfolio building based History : Portfolio building based on In licensing on In licensing Sep. 2000 Incorporated MediciNova, Inc. in San Diego, CA June 2001 Initiated research collaboration with Institute of Medical Sciences at University of Tokyo Mar. 2002 In licensed MN 001 from Kyorin Pharmaceutical June 2002 In licensed MN 029 from Angiogene Pharmaceuticals Feb. 2004 In licensed MN 221 from Kissei Pharmaceutical Apr. 2004 In licensed MN 305 from Mitsubishi Pharma Corp Oct. 2004 In licensed MN 166 from Kyorin Pharmaceutical Dec. 2004 In licensed MN 246 from Mitsubishi Pharma Corp Oct. 2006 In licensed MN 447/462 from Meiji Seika Kaisha, Ltd.
MediciNova, Inc. *Source: Internal MediciNova projections Business Model Business Model In License therapeutic small molecules from Japan to develop in US/EU for global markets In License: Product candidates with significant clinical or preclinical data Development: Conduct Proof of Concept (Phase I and Phase II) clinical trials Two Pathways to ROI: 1.
You are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date September 28, 2010. MediciNova disclaims any intent or obligation to revise or update these forward looking statements. MediciNova, Inc. 2010 3 MediciNova Overview: Founded in September 2000 Headquartered in San Diego, CA Additional office in Tokyo, Japan Dual listing on NasdaqGM as MNOV and Osaka Securities Exchange as 4875 $63.3 million Market Cap (NasdaqGM) as of 9/28/2010 Development Company Focused on Differentiated Product Candidates Unique access to differentiated, potentially high value assets primarily from Japanese alliances (Kyorin, Kissei, Mitsubishi Tanabe Pharma, Meiji) New Approaches to Treat Serious Medical Conditions: MN 221: Intravenous (IV) acute asthma and COPD candidate Potential $1 billion+ combined market opportunity worldwide* MN 166: oral multiple sclerosis, neuropathic pain, drug addiction candidate Corporate Overview: Corporate Overview: MediciNova, Inc.
These forward looking statements may be preceded by, followed by or otherwise include the words believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, or similar expressions. Actual results or events may differ materially from those expressed or implied in any forward looking statements due to various factors, including the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities; the timing of expected filings with the FDA; MediciNova s failure to execute strategic plans or strategies successfully; MediciNova s collaborations with third parties; MediciNova s ability to realize the anticipated strategic and financial benefits from its acquisition of Avigen, Inc., to integrate the two ibudilast development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program; the availability of funds to complete product development plans and MediciNova s ability to raise sufficient capital when needed, or at all; intellectual property or contract rights; and the other risks and uncertainties described in MediciNova s filings with the Securities and Exchange Commission, including MediciNova s annual report on Form 10 K for the year ended December 31, 2009 and its subsequent periodic reports on Forms 10 Q, 10 K and 8 K.
These forward looking statements include statements regarding MediciNova s clinical trials supporting the safety and efficacy of its product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources.
Accelerating the global development and commercialization of innovative pharmaceuticals MediciNova, Inc. 2010 Exhibit 99.1 MediciNova, Inc. 2010 Forward Looking Statements Forward Looking Statements 2 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.